| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 190.975 +18.34% on 12/23/25 | | 239.000 -5.44% on 01/21/26 | +27.000 (+13.57%) since 12/19/25 |
| 3-Month | 190.975 +18.34% on 12/23/25 | | 239.000 -5.44% on 01/21/26 | +6.000 (+2.73%) since 10/21/25 |
| 52-Week | 185.500 +21.83% on 04/09/25 | | 292.000 -22.60% on 07/29/25 | -1.000 (-0.44%) since 01/21/25 |
SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited...
— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase...
— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for...
Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today...
HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter...
— 49% ORR amongst SAVANNAH patients with higher MET levels —...
SAN DIEGO and SHANGHAI and HONG KONG and SYDNEY, Australia, July 06, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13)...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)...
| 3rd Resistance Point | 248.333 |
| 2nd Resistance Point | 243.667 |
| 1st Resistance Point | 234.333 |
| Last Price | 226.000 |
| 1st Support Level | 220.333 |
| 2nd Support Level | 215.667 |
| 3rd Support Level | 206.333 |
| 52-Week High | 292.000 |
| Fibonacci 61.8% | 251.317 |
| Fibonacci 50% | 238.750 |
| Fibonacci 38.2% | 226.183 |
| Last Price | 226.000 |
| 52-Week Low | 185.500 |